Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

4 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

5(62.5%)

Phase 1

3(37.5%)

8Total

Phase 2(5)

Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06494787Phase 2Withdrawn

A Phase 2 Study Using Aliya PEF Plus Pembro for Sarcoma

Role: lead

NCT03778996Phase 2Active Not Recruiting

SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma

Role: lead

NCT03886311Phase 2Recruiting

Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

Role: lead

NCT04165330Phase 1Active Not Recruiting

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Role: lead

NCT04535271Phase 2Recruiting

Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma

Role: lead

NCT03138161Phase 1Recruiting

SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

Role: lead

NCT03190174Phase 1Completed

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Role: lead

NCT05869994Withdrawn

Evaluation of Autologous Natural Killer Cell Activity in Primary Cancer Cell Cultures

Role: lead

NCT04535713Phase 2Recruiting

GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma

Role: lead

All 9 trials loaded